uniQure (NASDAQ:QURE) Stock Rating Lowered by Barclays

uniQure (NASDAQ:QURE) was downgraded by investment analysts at Barclays from an “overweight” rating to an “equal weight” rating in a report released on Monday, MarketBeat Ratings reports. They presently have a $28.00 price target on the biotechnology company’s stock, down from their prior price target of $60.00. Barclays‘s price objective would indicate a potential upside of 21.42% from the company’s previous close.

QURE has been the subject of a number of other reports. Wells Fargo & Company reissued an “overweight” rating and issued a $75.00 price target on shares of uniQure in a report on Tuesday, September 29th. Wolfe Research raised uniQure from a “peer perform” rating to an “outperform” rating and set a $65.00 price objective on the stock in a research note on Wednesday, July 29th. Weiss Ratings upgraded uniQure from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, September 21st. Cantor Fitzgerald raised shares of uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 target price for the company in a research note on Wednesday, June 17th. Finally, Royal Bank Of Canada reduced their target price on shares of uniQure from $65.00 to $48.00 and set an “outperform” rating on the stock in a report on Friday. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, uniQure has an average rating of “Moderate Buy” and a consensus target price of $53.73.

uniQure Trading Up 1.1%

Shares of QURE opened at $23.06 on Monday. The company has a debt-to-equity ratio of 0.15, a current ratio of 10.01 and a quick ratio of 10.01. uniQure has a 1-year low of $8.73 and a 1-year high of $71.50. The stock has a market cap of $1.60 billion, a price-to-earnings ratio of -5.75 and a beta of 1.06. The firm has a 50 day simple moving average of $42.72 and a 200-day simple moving average of $33.56.

uniQure (NASDAQ:QURE) last posted its earnings results on Wednesday, July 29th. The biotechnology company reported ($1.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.40). The company had revenue of $5.84 million during the quarter, compared to analysts’ expectations of $5.45 million. uniQure had a negative net margin of 1,350.73% and a negative return on equity of 111.96%. During the same period in the previous year, the company posted ($0.69) EPS. Equities analysts forecast that uniQure will post -3.82 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Avoro Capital Advisors LLC boosted its holdings in shares of uniQure by 38.4% during the fourth quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock worth $147,170,000 after purchasing an additional 1,705,556 shares during the last quarter. Orbimed Advisors LLC increased its stake in uniQure by 189.7% in the first quarter. Orbimed Advisors LLC now owns 2,136,149 shares of the biotechnology company’s stock valued at $34,926,000 after purchasing an additional 1,398,749 shares during the last quarter. Two Seas Capital LP purchased a new position in uniQure during the third quarter worth about $31,988,000. Artia Global Partners LP lifted its position in uniQure by 55.4% during the fourth quarter. Artia Global Partners LP now owns 1,023,539 shares of the biotechnology company’s stock worth $24,493,000 after buying an additional 364,700 shares during the period. Finally, Assenagon Asset Management S.A. boosted its stake in uniQure by 249.9% in the 2nd quarter. Assenagon Asset Management S.A. now owns 513,530 shares of the biotechnology company’s stock worth $23,653,000 after buying an additional 366,781 shares during the last quarter. Hedge funds and other institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on developing gene therapies intended to treat serious and potentially life-threatening diseases. The company uses adeno-associated virus (AAV) delivery technology to introduce genetic material into patients’ cells, with the goal of addressing the underlying causes of disease through a single administration.

uniQure’s lead commercial product, Hemgenix (etranacogene dezaparvovec), is a gene therapy for adults with hemophilia B who use factor IX replacement therapy.